Insights into defibrotide: an updated review

Bibliography

• Coccheri S, Biagi G. Defibrotide. Cardiovasc Drug Rev 1991;9:172-96
   Web of Science ®Google Scholar
• Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993;45:259-94
   PubMed Web of Science ®Google Scholar
• Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003;17:1636-42
   PubMed Web of Science ®Google Scholar
• Koehl GE, Geissler EK, Iacobelli M, et al. Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol Ther 2007;6:686-90
   PubMed Web of Science ®Google Scholar
• Coccheri S, Biagi G, Legnani C, et al. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 1988;35:151-6
   PubMed Web of Science ®Google Scholar
• Bianchi G, Barone D, Lanzarotti E, et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993;238:327-34
   PubMed Web of Science ®Google Scholar
• Bracht F, Schrör K. Isolation and functional characterization of DNA-derived aptamers that act as thrombin inhibitors in human platelets and coagulation assays. Agents Actions Suppl 1995;45:315-22
   PubMedGoogle Scholar
• Berti F, Rossoni G, Biasi G, et al. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins. Prostaglandins 1990;40:337-50
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 1994;71:507-10
   PubMed Web of Science ®Google Scholar
• Sato Y, Asada Y, Hara S, et al. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology 1999;34:66-70
   PubMed Web of Science ®Google Scholar
• Evangelista V, Piccardoni P, de Gaetano G, Cerletti C. Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes. Thromb Haemost 1992;67:660-4
   PubMed Web of Science ®Google Scholar
• Eissner G, Multhoff G, Gerbitz A, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002;100:334-40
   PubMed Web of Science ®Google Scholar
• Benimetskaya L, Wu S, Voskresenskiy AM, et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 2008;112:4343-52
   PubMed Web of Science ®Google Scholar
• Bertoldo U, Alberghina A, Verna C, et al. The action of defibrotide in the prevention of deep venous thrombosis. Minerva Chir 1988;43:57-60
   PubMedGoogle Scholar
• Lippi G, Viliani T, Alessandrello-Liotta A, et al. Defibrotide versus heparin in antithrombotic prophylaxis in gynaecological surgery. Minerva Med 1989;80:455-9
   PubMedGoogle Scholar
• Interdonato F, Festi L, Gerosa C, et al. The prevention of deep venous thromboses after radical or modified mastectomy interventions. Minerva Chir 1990;45:1389-92
   PubMedGoogle Scholar
• Rizzi A, Radaelli F, Pisano M, et al. Prevention of deep venous thrombosis with defibrotide in chest surgery. Controlled multicenter study versus heparin. Minerva Med 1987;78:745-750
   PubMedGoogle Scholar
• Villani LG, Dalla Valle R, Rubini P. Defibrotide and heparin in the prevention of deep venous thromboses. A controlled study. Minerva Chir 1990;45:1029-33
   PubMedGoogle Scholar
• Gerosa C, Calvani AB, Cornelli U, et al. A multicenter study of defibrotide in the prevention of deep venous thrombosis. Final results. Minerva Chir 1989;44:1507-16
   PubMedGoogle Scholar
• Ciavarella N, Ettorre C, Schiavoni M, et al. Effectiveness of defibrotide for prophylaxis of deep venous thrombosis in gynecological surgery: a double-blind, placebo-controlled clinical trial. Haemostasis 1986;16(suppl 1):39-41
   PubMedGoogle Scholar
• Milazzotto F, Carelli M, Citone C, et al. Use of defibrotide in the treatment of acute myocardial infarction. Semin Thromb Hemost 1989;15:464-9
   PubMed Web of Science ®Google Scholar
• Milazzotto F. Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction. Cardiovasc Drugs Ther 1993;7:809-16
   PubMed Web of Science ®Google Scholar
• Mattioli G, Cappello C, Fusaro MT. Treatment of acute myocardial infarction with defibrotide. Semin Thromb Hemost 1989;15:470-3
   PubMed Web of Science ®Google Scholar
• Arosio E, Pancera P, Zannoni M, et al. Defibrotide and peripheral obliterative arterial disease: preliminary data. Int J Clin Pharmacol Ther Toxicol 1989;27:526-59
   PubMedGoogle Scholar
• Violi F, Marubini E, Coccheri S, Nenci GG. Improvement of walking distance by defibrotide in patients with intermittent claudication--results of a randomized, placebo controlled study (the DICLIS study). Defibrotide Intermittent Claudication Italian Study. Thromb Haemost 2000;83:672-7
   PubMed Web of Science ®Google Scholar
• Burcoglu-O'Ral A, Erkan D, Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 2002;29:2006-11
   PubMed Web of Science ®Google Scholar
• Bayik MM, Akoglu T, Tuglular TF, et al. Treatment of thrombotic thrombocytopenic purpura with defibrotide. Am J Hematol 1993;43:74-5
   PubMed Web of Science ®Google Scholar
• Pogliani EM, Perseghin P, Parma M, et al. Defibrotide in recurrent thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost 2000;6:69-70
   PubMed Web of Science ®Google Scholar
• Ngirabacu MC, Kwan J, Leroy R, et al. Thrombotic microangiopathy after mllogeneic stem cell transplantation: a single centre experience [abstract]. Blood 2007;110:1669
   Google Scholar
• Bearman SI. The syndrome of hepatic veno-occlusive disease after bone marrow transplantation. Blood 1995;85:3005-20
   PubMed Web of Science ®Google Scholar
• Toh HC, McAfee SL, Sackstein R, et al. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 1999;24:891-5
   PubMed Web of Science ®Google Scholar
• Richardson PG, Guinana EC. Hepatic veno occlusive disease following hematopoietic stem cell transplantation. Acta Hematologica 2001;106:57-68
   PubMed Web of Science ®Google Scholar
• Ho VT, Linden E, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide and other current investigational therapies. Semin Thromb Hemost 2007;33:373-88
   PubMed Web of Science ®Google Scholar
• Falanga A. Tumor cell prothrombotic properties. Haemostasis 2001;31(suppl 1):1-4
   PubMedGoogle Scholar
• Bearman SI, Anderson GL, Mori M, et al. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11:1729-36
   PubMed Web of Science ®Google Scholar
• Tay J, Tinmouth A, Fergusson D, et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:206-17
   PubMed Web of Science ®Google Scholar
• Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gentuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001;92:406-13
   PubMed Web of Science ®Google Scholar
• Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venoocclusive disease with recombinant human issue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997;89:1501-6
   PubMed Web of Science ®Google Scholar
• Schlegel PG, Haber HP, Beck J, et al. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin. Ann Hematol 1998;76:37-41
   PubMed Web of Science ®Google Scholar
• Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998;92:737-44
   PubMed Web of Science ®Google Scholar
• Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000;111:1122-9
   PubMed Web of Science ®Google Scholar
• Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337-43
   PubMed Web of Science ®Google Scholar
• Richardson P, Soiffer R, Antin JH, et al. Defibrotide (Df) for the treatment of severe veno-occlusive disease (VOD) and multi-organ failure (MOF) post SCT: final results of a phase II, multicenter, randomized study and preliminary analyses of surrogate markers and ultrasound findings [abstract]. Blood 2004;104:350
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Lim ZY, Pagliuca A, et al. Incidence and management of hepatic veno-occlusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006;38:823-4
   PubMed Web of Science ®Google Scholar
• Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004;33:189-95
   PubMed Web of Science ®Google Scholar
• Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic venoocclusive disease in children. Pediatr Blood Cancer 2007;48:700-4
   PubMed Web of Science ®Google Scholar
• Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006;91:795-800
   PubMed Web of Science ®Google Scholar
• Carreras E, Olavarria E, Neven B, et al. Defibrotide for the treatment of veno-occlusive disease post SCT: preliminary results of EU compassionate use program in 332 patients confirm promising activity and manageable toxicity [abstract]. Blood 2007;110:613
   Google Scholar
• Richardson P, Kernan N, Tomblyn M, et al. A Phase 3 randomized, historically-controlled clinical trial investigating the use of defibrotide in the treatment of severe veno-occlusive disease post-SCT: a novel approach to the validation of a promising new drug for the treatment of a life threatening disease [abstract]. Blood 2007;110(11):614
   Web of Science ®Google Scholar
• de Fontbrune FS, Mal H, Dauriat G, et al. Veno-occlusive disease of the liver after lung transplantation. Am J Transplant 2007;7:2208-11
   PubMed Web of Science ®Google Scholar
• Bischof M, Zierhut D, Gutwein S, et al. Veno-occlusive liver disease after total infradiaphragmatic lymphoid irradiation. A rare complication. Strahlenther Onkol 2001;177:296-301
   PubMed Web of Science ®Google Scholar
• Versluys B, Bhattacharaya R, Steward C, et al. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004;103:1968
   PubMed Web of Science ®Google Scholar
• Corbacioglu S, Honig M, Lahr G, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 2006;38:547-53
   PubMed Web of Science ®Google Scholar
• Dignan F, Gujral D, Ethell M, et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007;40:79-82
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Roosnek E, Mermillod B, et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004;10:347-54
   PubMed Web of Science ®Google Scholar
• Bonini A, Avanzini P, Masini L, et al. Defibrotide low-dose continuous infusion from day + 1 until day + 21 after allogeneic stem cell transplantation as prophylaxis of veno-occlusive disease (VOD) of the liver. A single centre experience [abstract]. Blood 2007;110(11):4927
   Google Scholar
• Milone G, Poidomani M, Coppoletta S, et al. Defibrotide in prevention of liver toxicity in patients at high risk of VOD after HSC transplantation [abstract]. Blood 2008;112(11):3275
   Google Scholar
• Marktel S, Chiesa R, Cappelli B, et al. Optimal thalassemia free survival and minimal regimen related toxicity in 50 consecutive transplants of high risk beta thalassemia pediatric patients using myelablative therapy with intravenous busulphan [abstract]. Blood 2008;112(11):3266
   Google Scholar
• Morabito A, Sarmiento R, Bonginelli P, Gasparini G. Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol Hemtaol 2004;49:91-107
   PubMed Web of Science ®Google Scholar
• Bunka DH, Stockley PG. Aptamers come of age–at last. Nat Rev Microbiol 2006;4:588-96
   PubMed Web of Science ®Google Scholar
• Gottfried E, Kreutz M, Haffner S, et al. Differentiation of human tumour-associated dendritic cells into endothelial-like cells: an alternative pathway of tumour angiogenesis. Scand J Immunol 2007;65:329-35
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mc Millin D, Kippel S, et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin N Am 2007;21:1007-27
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol 2007;20:797-816
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Rouleau C, Menon K, et al. Defibrotide targets tumor micronevironmental interaction and sensitizes multiple myeloma and solid tumor cells to cytotoxic chemotherapy [abstract]. Blood (ASH) 2004;104:286
   Google Scholar
• Mitsiades CS, Benimetskaya L, Menon K, et al. Defibrotide, an orally bioavailable modulator of myeloma tumor microenvironment interactions: molecular sequelae and clinical implications [abstract]. Blood (ASH) 2006;108:3523
   Google Scholar
• Echart C, Distaso M, Ferro L, et al. Defibrotide induces downregulation of heparanase expression in multiple myeloma cell lines: a novel mechanism of action. Haematologica 2007;92(suppl 2):146
   Web of Science ®Google Scholar
• Mitsiades CS, Rouleau C, Echart C, et al. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res 2009;15:1210-21
   PubMed Web of Science ®Google Scholar
• Echart C, Graziadio B, Repice C, et al. Defibrotide counteracts the modifications of antithrombotic phenotype of endothelial cells induced by thalidomide [abstract]. Blood 2007;110(11):2502
   Google Scholar
• Palumbo A, Larocca A, Rus C, et al. A Phase I/II trial on melphalan, prednisone, thalidomide, defibrotide combination in relapsed/refractory multiple myeloma patients [abstract]. Blood 2007;110(11):2715
   Web of Science ®Google Scholar
• Ferrari PA, Cornelli U, Dina F, et al. Defibrotide in the prevention of deep venous thrombosis in general surgery. Preliminary results of a multicenter study. Minerva Med 1988;79:551-61
   PubMedGoogle Scholar
• Ulutin ON, Cizmeci G, Balkuv-Ulutin S. Clinical pharmacology and mode of action of a new antithrombotic compound: defibrotide. Folia Haematol Int Mag Klin Morphol Blutforsch 1988;115:177-80
   PubMedGoogle Scholar
• Rossi R, Farma A, Maggi GC, Marelli A. Pharmacokinetics of defibrotide in uremic patients undergoing hemodialysis. Minerva Med 1991;82:853-7
   PubMedGoogle Scholar
• Qureshi A, Marshall L, Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 2008;50:831-2
   PubMed Web of Science ®Google Scholar